The market for anthrax vaccines is expected to exhibit a compound annual growth rate (CAGR) of 7.4% in terms of value from 2020 to 2028, reaching a valuation of USD 1.01 Billion. This growth is attributed to the rising prevalence of infectious diseases such as anthrax on a global scale. Moreover, the cost-effectiveness of immunizations, coupled with new investment...